The first episode of The Biotech Pulse concentrates on the Manufacturing of Complex Bioligics. Forbion General Partner Rogier Rooswinkel speaks to Replimune CEO Philip Astley-Sparke. Philip Astley-Sparke is not only the company's Chief Executive Officer, but he is also its co-founder and has served as a member of its Board since its formation in 2015. Philip was previously the President and CEO of BioVex Inc that developed the first oncolytic therapy which was approved in the U.S. and Europe in 2015. Biovex was acquired by Amgen for up to $1bn in 2011. Tune in to listen to Philip's insight about Contract Development and Manufacturing Organizations (CDMOs) and when to recognize how and when is the right time to go it alone.

See omnystudio.com/listener for privacy information.